Press releases
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia
- Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
- Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
Key statistics
On Wednesday, Geron Corp (GERN:DEU) closed at 3.97, -23.71% below its 52-week high of 5.20, set on Jun 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.82 |
---|---|
High | 4.05 |
Low | 3.81 |
Bid | 3.98 |
Offer | 4.11 |
Previous close | 3.86 |
Average volume | 4.92k |
---|---|
Shares outstanding | 593.13m |
Free float | 592.61m |
P/E (TTM) | -- |
Market cap | 2.47bn USD |
EPS (TTM) | -0.3464 USD |
Data delayed at least 15 minutes, as of Jul 03 2024.
More ▼